209 related articles for article (PubMed ID: 26245639)
1. Cell division inhibitors with efficacy equivalent to isoniazid in the acute murine Mycobacterium tuberculosis infection model.
Knudson SE; Awasthi D; Kumar K; Carreau A; Goullieux L; Lagrange S; Vermet H; Ojima I; Slayden RA
J Antimicrob Chemother; 2015 Nov; 70(11):3070-3. PubMed ID: 26245639
[TBL] [Abstract][Full Text] [Related]
2. A trisubstituted benzimidazole cell division inhibitor with efficacy against Mycobacterium tuberculosis.
Knudson SE; Awasthi D; Kumar K; Carreau A; Goullieux L; Lagrange S; Vermet H; Ojima I; Slayden RA
PLoS One; 2014; 9(4):e93953. PubMed ID: 24736743
[TBL] [Abstract][Full Text] [Related]
3. In vitro-in vivo activity relationship of substituted benzimidazole cell division inhibitors with activity against Mycobacterium tuberculosis.
Knudson SE; Kumar K; Awasthi D; Ojima I; Slayden RA
Tuberculosis (Edinb); 2014 May; 94(3):271-6. PubMed ID: 24746463
[TBL] [Abstract][Full Text] [Related]
4. Formulation studies of InhA inhibitors and combination therapy to improve efficacy against Mycobacterium tuberculosis.
Knudson SE; Cummings JE; Bommineni GR; Pan P; Tonge PJ; Slayden RA
Tuberculosis (Edinb); 2016 Dec; 101():8-14. PubMed ID: 27865404
[TBL] [Abstract][Full Text] [Related]
5. Antimycobacterial activity of novel 1-(5-cyclobutyl-1,3-oxazol-2-yl)-3-(sub)phenyl/pyridylthiourea compounds endowed with high activity toward multidrug-resistant Mycobacterium tuberculosis.
Sriram D; Yogeeswari P; Dinakaran M; Thirumurugan R
J Antimicrob Chemother; 2007 Jun; 59(6):1194-6. PubMed ID: 17449482
[TBL] [Abstract][Full Text] [Related]
6. Identification of a new antitubercular drug candidate, SQ109, from a combinatorial library of 1,2-ethylenediamines.
Protopopova M; Hanrahan C; Nikonenko B; Samala R; Chen P; Gearhart J; Einck L; Nacy CA
J Antimicrob Chemother; 2005 Nov; 56(5):968-74. PubMed ID: 16172107
[TBL] [Abstract][Full Text] [Related]
7. Isoniazid pharmacokinetics-pharmacodynamics in an aerosol infection model of tuberculosis.
Jayaram R; Shandil RK; Gaonkar S; Kaur P; Suresh BL; Mahesh BN; Jayashree R; Nandi V; Bharath S; Kantharaj E; Balasubramanian V
Antimicrob Agents Chemother; 2004 Aug; 48(8):2951-7. PubMed ID: 15273105
[TBL] [Abstract][Full Text] [Related]
8. Enhancement of in vitro activity of tuberculosis drugs by addition of thioridazine is not reflected by improved in vivo therapeutic efficacy.
de Knegt GJ; ten Kate MT; van Soolingen D; Aarnoutse R; Boeree MJ; Bakker-Woudenberg IA; de Steenwinkel JE
Tuberculosis (Edinb); 2014 Dec; 94(6):701-7. PubMed ID: 25621361
[TBL] [Abstract][Full Text] [Related]
9. Activity of IQG-607, a new orally active compound, in a murine model of Mycobacterium tuberculosis infection.
Rodrigues-Junior VS; Dos Santos Junior A; Dos Santos AJ; Schneider CZ; Calixto JB; Sousa EH; de França Lopes LG; Souto AA; Basso LA; Santos DS; Campos MM
Int J Antimicrob Agents; 2012 Aug; 40(2):182-5. PubMed ID: 22748570
[TBL] [Abstract][Full Text] [Related]
10. Discovery of Novel Oral Protein Synthesis Inhibitors of Mycobacterium tuberculosis That Target Leucyl-tRNA Synthetase.
Palencia A; Li X; Bu W; Choi W; Ding CZ; Easom EE; Feng L; Hernandez V; Houston P; Liu L; Meewan M; Mohan M; Rock FL; Sexton H; Zhang S; Zhou Y; Wan B; Wang Y; Franzblau SG; Woolhiser L; Gruppo V; Lenaerts AJ; O'Malley T; Parish T; Cooper CB; Waters MG; Ma Z; Ioerger TR; Sacchettini JC; Rullas J; Angulo-Barturen I; Pérez-Herrán E; Mendoza A; Barros D; Cusack S; Plattner JJ; Alley MR
Antimicrob Agents Chemother; 2016 Oct; 60(10):6271-80. PubMed ID: 27503647
[TBL] [Abstract][Full Text] [Related]
11. In vitro and in vivo activities of a new lead compound I2906 against Mycobacterium tuberculosis.
Lu J; Yue J; Wu J; Luo R; Hu Z; Li J; Bai Y; Tang Z; Xian Q; Zhang X; Wang H
Pharmacology; 2010; 85(6):365-71. PubMed ID: 20530976
[TBL] [Abstract][Full Text] [Related]
12. Design and synthesis of antituberculars: preparation and evaluation against Mycobacterium tuberculosis of an isoniazid Schiff base.
Hearn MJ; Cynamon MH
J Antimicrob Chemother; 2004 Feb; 53(2):185-91. PubMed ID: 14688045
[TBL] [Abstract][Full Text] [Related]
13. Identification of anti-tuberculosis agents that target the cell-division protein FtsZ.
Lin Y; Zhu N; Han Y; Jiang J; Si S
J Antibiot (Tokyo); 2014 Sep; 67(9):671-6. PubMed ID: 24984796
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and biological evaluation of new imidazo[2,1-b][1,3,4]thiadiazole-benzimidazole derivatives.
Ramprasad J; Nayak N; Dalimba U; Yogeeswari P; Sriram D; Peethambar SK; Achur R; Kumar HS
Eur J Med Chem; 2015 May; 95():49-63. PubMed ID: 25794789
[TBL] [Abstract][Full Text] [Related]
15. Rapid, simple in vivo screen for new drugs active against Mycobacterium tuberculosis.
Nikonenko BV; Samala R; Einck L; Nacy CA
Antimicrob Agents Chemother; 2004 Dec; 48(12):4550-5. PubMed ID: 15561824
[TBL] [Abstract][Full Text] [Related]
16. Novel, potent, orally bioavailable and selective mycobacterial ATP synthase inhibitors that demonstrated activity against both replicating and non-replicating M. tuberculosis.
Singh S; Roy KK; Khan SR; Kashyap VK; Sharma A; Jaiswal S; Sharma SK; Krishnan MY; Chaturvedi V; Lal J; Sinha S; Dasgupta A; Srivastava R; Saxena AK
Bioorg Med Chem; 2015 Feb; 23(4):742-52. PubMed ID: 25614114
[TBL] [Abstract][Full Text] [Related]
17. In vitro and in vivo activities of levofloxacin against Mycobacterium tuberculosis.
JI B; Lounis N; Truffot-Pernot C; Grosset J
Antimicrob Agents Chemother; 1995 Jun; 39(6):1341-4. PubMed ID: 7574527
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of gyrase B as a drug target in Mycobacterium tuberculosis.
Chopra S; Matsuyama K; Tran T; Malerich JP; Wan B; Franzblau SG; Lun S; Guo H; Maiga MC; Bishai WR; Madrid PB
J Antimicrob Chemother; 2012 Feb; 67(2):415-21. PubMed ID: 22052686
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and in vitro and in vivo antimycobacterial activity of isonicotinoyl hydrazones.
Sriram D; Yogeeswari P; Madhu K
Bioorg Med Chem Lett; 2005 Oct; 15(20):4502-5. PubMed ID: 16115763
[TBL] [Abstract][Full Text] [Related]
20. Physicochemical, pharmacokinetic, efficacy and toxicity profiling of a potential nitrofuranyl methyl piperazine derivative IIIM-MCD-211 for oral tuberculosis therapy via in-silico-in-vitro-in-vivo approach.
Magotra A; Sharma A; Singh S; Ojha PK; Kumar S; Bokolia N; Wazir P; Sharma S; Khan IA; Singh PP; Vishwakarma RA; Singh G; Nandi U
Pulm Pharmacol Ther; 2018 Feb; 48():151-160. PubMed ID: 29174840
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
